Seqirus Inc., of Summit, N.J., disclosed a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine was 36.2 percent more effective than standard egg-based quadrivalent vaccine in preventing influenza-like illness captured within primary care visits in people aged 4 years and above during the 2017-18 influenza season in the U.S., a season characterized by egg-adapted changes.